Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking several high-profile Wall Street picks and putting them under the microscope. Investment banker Goldman Sachs plunged back into the world of big pharma stocks this morning. Initiating coverage of seven biotech and pharmaceutical companies running nearly the length of the alphabet from ...
READ MORE
|
A report has identified a two-tier manufacturing market and forecast increased acquisitions by Indian companies, along with a notable improvement in the international reputation of Indian made pharmaceuticals, but perhaps most dramatically, a large majority of domestic companies called for urgent government support to invest in active pharmaceutical ingredient (API) sites....
READ MORE
|
Impeachment may be the only thing on the news these days, but it’s certainly not the only thing happening in Congress. On Dec. 12, the U.S. House passed H.R. 3 , the Lower Drug Costs Now Act. This is the most significant stand-alone prescription drug bill to pass either chamber of Congress since 2003. In a nutshell, the Lower Drug Costs Now Act gives Medicare the power to negotiate directly with pharmaceutical companies to bring down the price of some of the most heavily purchased medicati...
READ MORE
|
The companies—Turing Pharmaceuticals, Retrophin, Valeant Pharmaceuticals International and Rodelis Therapeutics—targeted decades-old, off-patent drugs, monopolized both their production and distribution, and held dying patients and their health care providers hostage as they hiked prices, often overnight, by tenfold or greater. All four companies were headed by veteran hedge fund traders and were run as such....
WWW.WSWS.ORG/
READ MORE
|
Australian nurses have attended more than 46,000 events run by pharmaceutical companies in four years, a study has found....
THEGUARDIAN.COM
READ MORE
|
Ahead of being absorbed by Bristol-Myers Squibb, Celgene forged a strategic collaboration with two companies to develop immuno-oncology treatments and cell therapies. First, Celgene struck a deal with Boston-based Kyn Therapeutics to develop novel immuno-oncology therapies. Celgene provided $80 million in an upfront payment, as well as an equity investment to exclusively license Kyn’s Kynase (kynurenine-degrading enzyme) and aryl hydrocarbon receptor (AHR) antagonist programs. The companie...
READ MORE
|